ORIG3N Lands $5,105,000 New Financing

  • Feed Type
  • Date
    12/9/2015
  • Company Name
    ORIG3N
  • Mailing Address
    27 Drydock Ave. 6th Floor Boston, MA 02210 USA
  • Company Description
    Boston based ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based upon Nobel Prize winning technology.
  • Website
    http://www.orig3n.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,105,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy